Article info

Download PDFPDF

Original research
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

Authors

  1. Correspondence to Dr Kristen Sweet; ksweet1{at}its.jnj.com
View Full Text

Citation

Sweet K, Song Q, Loza MJ, et al
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

Publication history

  • Received March 26, 2021
  • Revision received April 20, 2021
  • Accepted April 20, 2021
  • First published May 19, 2021.
Online issue publication 
May 19, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.